-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7

Benzinga·08/28/2026 17:17:29
Listen to the news
Roth Capital analyst Boobalan Pachaiyappan maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $8 to $7.